Posted inBiotechnology
Early Smoking Habits Heighten Risk of COPD in Adulthood
Childhood Smoking and Its Alarming Link to Chronic Obstructive Pulmonary Disease (COPD) Research has illuminated the troubling impact of childhood…
Posted inBiotechnology
MD Anderson and Myriad Genetics Join Forces to Assess Clinical Utility of Myriad’s Molecular Residual Disease Assay
The University of Texas MD Anderson Cancer Center has strategically aligned itself with Myriad Genetics, Inc. in a groundbreaking partnership…
Posted inBiotechnology
Global Collaboration Set to Offer Premier Osteopathy Training
The University of Plymouth and International Osteopathic Education (IOE) are embarking on an innovative partnership aimed at revolutionizing osteopathic education…
Posted inBiotechnology
AbbVie exercises first $40 million option to advance Capsida-partnered CNS gene therapy
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised…
Posted inBiotechnology
Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to…
Posted inBiotechnology
Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to…
Posted inBiotechnology
Aviceda raises $207M series C to take geographic atrophy drug through phase 3
Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this…
Posted inBiotechnology
Candid’s T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M
Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925…
Posted inBiotechnology
UCLA Researchers Discover Genetic Markers for Early Detection of Adolescent Psychosis
In a groundbreaking interview featured in Genomic Press, Dr. Carrie E. Bearden, a distinguished Professor of Psychiatry and Biobehavioral Sciences…
Posted inBiotechnology
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit.…